ADMA Biologics Sees Unusually High Options Volume (NASDAQ:ADMA)

ADMA Biologics Inc (NASDAQ:ADMA) was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 22,398 call options on the stock. This is an increase of approximately 848% compared to the typical daily volume of 2,362 call options.

Insider Buying and Selling

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steve Elms purchased 7,000 shares of the stock in a transaction on Thursday, March 5th. The shares were purchased at an average price of $15.67 per share, with a total value of $109,690.00. Following the acquisition, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. American Century Companies Inc. lifted its stake in shares of ADMA Biologics by 8.4% in the 2nd quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock worth $83,966,000 after acquiring an additional 358,627 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of ADMA Biologics by 24.9% in the third quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after acquiring an additional 826,415 shares in the last quarter. Ranger Investment Management L.P. increased its stake in shares of ADMA Biologics by 49.1% during the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock worth $43,529,000 after acquiring an additional 786,865 shares during the period. Boothbay Fund Management LLC acquired a new position in shares of ADMA Biologics during the third quarter worth about $11,334,000. Finally, WINTON GROUP Ltd raised its holdings in ADMA Biologics by 302.8% during the second quarter. WINTON GROUP Ltd now owns 272,817 shares of the biotechnology company’s stock worth $4,968,000 after purchasing an additional 205,094 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

ADMA has been the topic of several recent analyst reports. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a report on Thursday. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Two investment analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $32.00.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA publicly refuted Culper Research’s allegations, saying the short‑seller misunderstand the company’s business and the role of its ASCENIV product — the company’s rebuttal could stabilize investor sentiment if followed by clarifying disclosures. ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
• Positive Sentiment: Unusual bullish options activity was reported (large spike in call purchases), indicating some speculative or informed buyers are betting on a rebound or corrective move after the sell‑off.
• Neutral Sentiment: Some analysts and commentators note the stock may be oversold and technically poised for a bounce, but that view is contingent on resolution of the allegations and legal inquiries. Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
• Negative Sentiment: The Culper Research short report alleging channel stuffing appears to be the catalyst for the sell‑off; short reports can lead to sharp, sustained pressure until disproven. ADMA Biologics extends selloff as Cantor downgrades after short report
• Negative Sentiment: Multiple law firms and plaintiff‑side notices have announced securities‑fraud investigations and shareholder alerts (BFA Law, Glancy Prongay Wolke & Rotter, Pomerantz, Holzer & Holzer, Ademi LLP, others) — this increases potential litigation risk and ongoing headline pressure. ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report — Investors Notified to Contact BFA Law Securities-Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced
• Negative Sentiment: Cantor Fitzgerald and other market participants moved to downgrade or flag the name after the report, adding analyst pressure to the stock while investigations and media coverage continue. Cantor Fitzgerald downgrades ADMA Biologics (ADMA)

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $8.29 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $25.67. The company has a market capitalization of $1.97 billion, a PE ratio of 13.82 and a beta of 0.51. The company has a fifty day moving average of $15.76 and a two-hundred day moving average of $16.47.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the previous year, the firm earned $0.46 earnings per share. The business’s revenue was up 18.4% compared to the same quarter last year. As a group, analysts expect that ADMA Biologics will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.